Regeneron Pharmaceuticals, Inc. REGN shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler. Several analysts also lowered their price targets on the stock.
What To Know: The issuance of the CRL effectively denied the company approval of a higher-dose version of EYLEA.
- Canaccord Genuity analyst John Newman downgraded Regeneron Pharmaceuticals from Buy to Hold and lowered the price target from $953 to $720.
- Barclays analyst Carter Gould maintained Regeneron Pharmaceuticals with a Overweight and lowered the price target from $915 to $888.
- RBC Capital analyst Brian Abrahams maintained Regeneron Pharmaceuticals with a Sector Perform and lowered the price target from $816 to $789.
- Baird analyst Brian Skorney maintained Regeneron Pharmaceuticals with a Neutral and lowered the price target from $800 to $760.
- Truist Securities analyst Robyn Karnauskas maintained Regeneron Pharmaceuticals with a Buy and lowered the price target from $1050 to $1045.
Related Link: Google Accused of Breaching Promised Ad Standards, Big Brands and Government Agencies Affected
REGN Price Action: Shares of REGN were down 2.38% at $699.04 at the time of publication, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
